Immutep Ltd (AU:IMM) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Immutep Limited has released promising results from its INSIGHT-003 trial, showcasing the efficacy of its immunotherapy treatment, eftilagimod alpha, in combination with pembrolizumab and chemotherapy for non-small cell lung cancer. The trial demonstrated a median overall survival of 32.9 months and a 24-month survival rate of 81%, significantly outperforming historical controls. The positive safety profile and improved response rates underscore the potential of efti to enhance existing cancer treatments.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
